Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy
In the past decade, the development of two innovative technologies, namely, induced pluripotent stem cells (iPSCs) and the CRISPR Cas9 system, has enabled researchers to model diseases derived from patient cells and precisely edit DNA sequences of interest, respectively. In particular, Duchenne musc...
Saved in:
Main Authors: | Peter Gee (Author), Huaigeng Xu (Author), Akitsu Hotta (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2017-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9
by: Tingting Sui, et al.
Published: (2018) -
A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing
by: Yu Zhang, et al.
Published: (2022) -
Genome Editing-Mediated Utrophin Upregulation in Duchenne Muscular Dystrophy Stem Cells
by: Kasturi Sengupta, et al.
Published: (2020) -
Delivery strategies for CRISPR/Cas genome editing tool for retinal dystrophies: challenges and opportunities
by: Aayushi Lohia, et al.
Published: (2022) -
Precision Medicine and Exercise Therapy in Duchenne Muscular Dystrophy
by: Matthew Kostek
Published: (2019)